FAQ

INCB028050

Known as: INCB 028050 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2015
01220102015

Related topics

Related topics

1 relation

Broader (1)

baricitinib

Related mentions per year

Related mentions per year

2010-2018
201020122014201620182020
INCB028050
baricitinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
OBJECTIVES To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral inhibitor of JAK1/JAK2 in patients with… (More)
Is this relevant?
2014
2014
The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers.
Baricitinib (also known as LY3009104 or INCB028050), a novel and potent small molecule inhibitor of Janus kinase family of… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2013
2013
Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.
Janus kinase (JAK) inhibitors have been developed as anti-inflammatory agents and have demonstrated clinical efficacy in… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases… (More)
Is this relevant?
2010
2010
Preclinical Characterization of INCB028050 Efficacious in Rodent Models of Arthritis: Selective Inhibition of JAK1 and JAK2 Is
 
  • table I
  • figure 1
  • figure 2
  • figure 3
  • table II
Is this relevant?